- Home
- MYNZ vs INDP Comparison
MYNZ vs INDP Comparison
Compare MYNZ & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- INDP
- Stock Information
- Founded
- MYNZ 2021
- INDP 2000
- Country
- MYNZ Germany
- INDP United States
- Employees
- MYNZ N/A
- INDP N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- INDP Health Care
- Exchange
- MYNZ Nasdaq
- INDP Nasdaq
- Market Cap
- MYNZ 10.5M
- INDP 8.8M
- IPO Year
- MYNZ 2021
- INDP N/A
- Fundamental
- Price
- MYNZ $3.44
- INDP $0.50
- Analyst Decision
- MYNZ Buy
- INDP Strong Buy
- Analyst Count
- MYNZ 3
- INDP 2
- Target Price
- MYNZ $14.00
- INDP $8.50
- AVG Volume (30 Days)
- MYNZ 177.3K
- INDP 1.2M
- Earning Date
- MYNZ 04-15-2025
- INDP 03-13-2025
- Dividend Yield
- MYNZ N/A
- INDP N/A
- EPS Growth
- MYNZ N/A
- INDP N/A
- EPS
- MYNZ N/A
- INDP N/A
- Revenue
- MYNZ $893,991.00
- INDP N/A
- Revenue This Year
- MYNZ $20.94
- INDP N/A
- Revenue Next Year
- MYNZ $18.01
- INDP N/A
- P/E Ratio
- MYNZ N/A
- INDP N/A
- Revenue Growth
- MYNZ N/A
- INDP N/A
- 52 Week Low
- MYNZ $0.18
- INDP $0.47
- 52 Week High
- MYNZ $8.20
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- MYNZ 37.70
- INDP 24.26
- Support Level
- MYNZ $2.72
- INDP $0.58
- Resistance Level
- MYNZ $5.34
- INDP $0.78
- Average True Range (ATR)
- MYNZ 0.55
- INDP 0.14
- MACD
- MYNZ -0.12
- INDP -0.03
- Stochastic Oscillator
- MYNZ 27.48
- INDP 1.89
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.